PMID: 8794994Apr 1, 1996

The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016

The Journal of Pharmacy and Pharmacology
M J HagertyK A Kane


AM 92016 (1-(4-methanesulphonamidophenoxy)- 3-(N-methyl-3-4-dichlorophenethylamino)-2-propanol benzoic acid salt), an oxypropanolamine analogue of sotalol, has been shown to possess Class III anti-arrhythmic properties in-vitro at concentrations showing 1000 times more potency than sotalol. The aim of this study was to characterize the effects of AM 92016 in-vivo. When administered to anaesthetized guinea-pigs, AM 92016 (10 micrograms kg-1 -5 mg kg-1) significantly increased heart rate, systolic arterial blood pressure, left ventricular systolic pressure and the contractile index dp dtmax. AM 92016 also significantly decreased the QT interval of the electrocardiogram from 135 +/- 10 to 105 +/- 4 ms (5 mg kg-1). The time to onset of the first arrhythmia and ventricular fibrillation, induced by intravenous infusion of ouabain, was shortened in the presence of AM 92016. Ouabain-induced ventricular fibrillation occurred at 18 +/- 5 and 12 +/- 3 min (P < 0.05) in control and AM 92016-(1 mg kg-1) treated guinea-pigs, respectively. An infusion of AM 92016 (2.5 micrograms kg-1 min-1) to anaesthetized pigs significantly increased the total number of arrhythmias occurring following coronary artery occlusion from 266 +/- 26 in control pig...Continue Reading


Jan 1, 1992·Journal of Cardiovascular Pharmacology·H S RasmussenH W Dalrymple
Jun 1, 1969·British Journal of Pharmacology·A N DohadwallaE M Vaughan Williams
Jan 1, 1993·Journal of Cardiovascular Pharmacology·C L Wainwright, P A Martorana
Jun 1, 1993·British Journal of Pharmacology·C L WainwrightH Van Belle


Jun 18, 2005·Journal of Pharmacological and Toxicological Methods·Daniela S HauserGuido Hanauer

Related Concepts

1-(4-methanesulfonamidophenoxy)-3--(N-methyl-3,4-dichlorophenylethylamino)-2-propanol, benzoic acid salt
Insufflation Anesthesia
Cardiac Depressants
Cardiac Arrhythmia
Diastolic Blood Pressure
Cavia porcellus
Pulse Rate
Myocardial Contraction

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.